Endo International PLC (NASDAQ:ENDP) had its price target trimmed by Citigroup Inc. from $40.00 to $25.00 in a report released on Friday. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also weighed in on ENDP. JPMorgan Chase & Co. set a $40.00 target price on Endo International PLC and gave the company a buy rating in a report on Tuesday, August 9th. Leerink Swann reaffirmed a hold rating and set a $22.00 target price (down previously from $23.00) on shares of Endo International PLC in a report on Tuesday, August 9th. Oppenheimer Holdings Inc. reaffirmed a hold rating on shares of Endo International PLC in a report on Wednesday, June 29th. Mizuho raised Endo International PLC from a neutral rating to a buy rating and lifted their target price for the company from $16.00 to $29.00 in a report on Friday, August 12th. Finally, Vetr lowered Endo International PLC from a strong-buy rating to a buy rating and set a $19.14 target price for the company. in a report on Thursday, July 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $39.32.

Endo International PLC (NASDAQ:ENDP) opened at 20.29 on Friday. The firm’s market cap is $4.52 billion. The stock has a 50 day moving average price of $20.98 and a 200 day moving average price of $22.03. Endo International PLC has a 1-year low of $12.56 and a 1-year high of $77.21.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The company earned $921 million during the quarter, compared to analyst estimates of $873.50 million. During the same quarter last year, the firm posted $1.08 EPS. The firm’s revenue for the quarter was up 25.3% on a year-over-year basis. On average, analysts anticipate that Endo International PLC will post $4.56 EPS for the current year.

A number of hedge funds have recently modified their holdings of the company. Advantus Capital Management Inc boosted its stake in shares of Endo International PLC by 2.4% in the second quarter. Advantus Capital Management Inc now owns 19,932 shares of the company’s stock worth $311,000 after buying an additional 461 shares during the last quarter. Aperio Group LLC boosted its stake in shares of Endo International PLC by 1.7% in the first quarter. Aperio Group LLC now owns 43,200 shares of the company’s stock worth $1,216,000 after buying an additional 732 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Endo International PLC by 7.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 11,377 shares of the company’s stock valued at $320,000 after buying an additional 745 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in Endo International PLC by 5.5% in the first quarter. Riverhead Capital Management LLC now owns 32,435 shares of the company’s stock valued at $913,000 after buying an additional 1,694 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares in the last quarter. Institutional investors and hedge funds own 96.64% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.